New York, NY, May 07, 2021 (GLOBE NEWSWIRE) -- Facts and Factors have published a new research report titled “B-Cell Maturation Antigen (BCMA) Targeted Therapies Market by Product Type (CAR-T cell, ...

At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...

The Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by product type (CAR-T cell, bispecific antibodies, and antibody-drug conjugates), and by indication (acute lymphoblastic ...

Multiple myeloma is the most frequently occurring hematological malignancy which is characterized by the uncontrolled growth of plasma cells in bone marrow. The introduction of proteasome inhibitors ...

Dublin, Dec. 20, 2021 (GLOBE NEWSWIRE) -- The "Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's ...

B-cell maturation antigen (BCMA) or CD269 is an essential member of tumor necrosis factor receptor superfamily and is preferentially expressed in B lymphocytes. The factor is critical for the ...

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. We're excited in the multiple myeloma that ...